Summary of Use during Lactation

Prothionamide (protionamide) is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. No information is available on the use of prothionamide during breastfeeding. International sources consider breastfeeding to be acceptable during prothionamide use, but mothers should receive 100 mg of pyridoxine daily and the breastfed infant should receive pyridoxine 1 to 2 mg/kg once daily. Monitor the breastfed infant for gastrointestinal disturbances.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Anon. Ethionamide (Eto) or prothionamide (Pto). MSF Medical Guidelines 2026. https:​//medicalguidelines​.msf.org/en/viewport​/TUB/english/ethionamide-eto-or-prothionamide-pto-20324029​.html#section-target-3.

Substance Name

Prothionamide

CAS Registry Number

14222-60-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-infective Agents

Antitubercular Agents